Sopharma AD sells treasury shares worth BGN 68,969 on Bulgarian Stock Exchange

Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director Sopharma AD
Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director - Sopharma AD
0Comments

Sopharma AD has announced the sale of 28,500 of its own repurchased shares on July 30, 2025. The transaction took place on the Bulgarian Stock Exchange, with a total value of BGN 68,969.00 and an average price per share of BGN 2.42.

The company stated that these shares represent 0.01% of its share capital. Following this sale, Sopharma AD holds a total of 26,060,100 treasury shares, which accounts for 4.83% of its share capital.

According to the company’s notification: “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on July 30, 2025 the Company sold 28 500 (twenty-eight thousand five hundred) repurchased own shares representing 0.01% of the share capital of the Company, at a total value of BGN 68 969.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.42.”

The announcement was made in line with Article 17 of Regulation (EU) No 596/2014 regarding market abuse disclosure requirements.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.